What is the Alpa Laboratories PE ratio today?
Alpa Laboratories' PE ratio is 25.3 at the 29 October 2026 close (₹52.62 a share): a market capitalisation of ₹111 crore divided by consolidated net profit of ₹4.4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹15 crore) it is 7.4.
What is the Alpa Laboratories debt to equity ratio?
Alpa Laboratories' debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹2.5 crore against total equity of ₹186 crore. A year earlier, on 31 March 2025, it was 0.00.
What is the Alpa Laboratories net worth?
Alpa Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹186 crore on 31 March 2026, up 8.7% from ₹171 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹111 crore at the 29 October 2026 close.
What is the Alpa Laboratories PB ratio (price to book value)?
Alpa Laboratories' price-to-book (PB) ratio is 0.59 at the 29 October 2026 close: a market capitalisation of ₹111 crore divided by shareholders' equity (book value) of ₹186 crore on 31 March 2026. That is a book value of ₹88.53 per share against a share price of ₹52.62.
What is the Alpa Laboratories ROE and ROCE?
In FY26, Alpa Laboratories' return on equity (ROE) was 8.4% and its return on capital employed (ROCE) was 0.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.1% and ROCE 1.5%.
What is the Alpa Laboratories book value per share?
Alpa Laboratories' book value per share was ₹88.53 on 31 March 2026: shareholders' equity of ₹186 crore divided by the 2.1 crore shares in issue, up 8.7% from ₹81.48 a year earlier. The share price at the 29 October 2026 close was ₹52.62.
What is the Alpa Laboratories market cap?
Alpa Laboratories' market capitalisation was ₹111 crore at the 29 October 2026 close: 2.1 crore shares at ₹52.62 each.
Is Alpa Laboratories debt free?
No. Alpa Laboratories had borrowings of ₹2.5 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹138 crore, so it held net cash of ₹135 crore.
What is the Alpa Laboratories EPS?
Alpa Laboratories' basic earnings per share (EPS) were ₹6.71 in FY26, against ₹9.34 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹1.68.
What is the Alpa Laboratories promoter holding?
Promoters held 57.19% of Alpa Laboratories on 30 September 2026, unchanged from the previous quarter and down 0.10 percentage points from 57.29% a year earlier, according to the shareholding pattern filed with NSE.
What is the Alpa Laboratories free cash flow?
In FY26, Alpa Laboratories generated ₹10 crore of cash from operations and spent ₹4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹6 crore. In FY25 it was −₹4.3 crore.
What are the Alpa Laboratories latest quarterly results?
Alpa Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹98 lakh, down 91.7% from ₹11.8 crore in Q1 FY26; revenue from operations ₹23.9 crore, up 25.2% year on year.
What is the Alpa Laboratories shareholding pattern?
On 30 September 2026, Alpa Laboratories' shares were held by promoters 57.19%, foreign portfolio investors (FII/FPI) 0.35%, domestic institutions (DII) 0.07% (including mutual funds at 0.00%) and retail and other non-institutional investors 42.39%. Over the year, FII holding was unchanged.
What is the Alpa Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Alpa Laboratories' consolidated net profit was ₹15 crore, down 23.0% from ₹19.5 crore in FY25, on revenue from operations of ₹106 crore (down 5.9%). Over three years, from FY23, net profit was up 18.8%.
How does Alpa Laboratories compare with its peers?
On FY26 consolidated figures, against Bal Pharma, Krebs Biochemicals and Industries and Natural Capsules: Alpa Laboratories' operating margin of 1.1% is the second highest of the four (Bal Pharma 6.7%, Krebs Biochemicals and Industries −50.0%, Natural Capsules −10.0%; peer average −17.8%).
When are the Alpa Laboratories next results?
Alpa Laboratories has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
Alpa Laboratories vs Bal Pharma: how do they compare?
In FY26, Alpa Laboratories earned net profit of ₹15 crore on revenue of ₹106 crore, against ₹6.3 crore on ₹312 crore for Bal Pharma. Alpa Laboratories' operating margin was 1.1% (Bal Pharma 6.7%) and its return on equity 8.4% (Bal Pharma 7.9%). At the 29 October 2026 close, Alpa Laboratories' market capitalisation was ₹111 crore against ₹135 crore for Bal Pharma, and its PE ratio on FY26 profit 7.4 against 21.4.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
